It has been reported that the concentration of free placental growth factor (PlGF) is decreased and that of soluble fms-like tyrosine kinase 1 (sFlt-1) is increased before the onset of preeclampsia. However, no study has determined the reference values for sFlt-1 and free PlGF during pregnancy using a commercially avail- 
Introduction
Preeclampsia is associated with maternal and infantile morbidity and mortality (1, 2) . The early detection of high risk women may be clinically important. Advice could be given on what symptoms the patient should look for and how she might change her lifestyle; and preventive treatment with, for example, aspirin or antioxidants could be applied (3) . Preeclampsia is associated with a failure of trophoblasts to invade Whereas free VEGF concentrations are low throughout pregnancy (7), free PlGF concentrations increase during pregnancy (7) . Therefore, free PlGF, not free VEGF (8−11) , is considered pivotal for maintaining vascular endothelial cell homeostasis during pregnancy. In a nested case-control study as part of the Calcium for Preeclampsia Prevention Trial, it was disclosed that increased levels of sFlt-1 and reduced levels of free PlGF are potentially useful for predicting the subsequent development of preeclampsia (7) .
Torry et al. (12) reported reference values for PlGF during pregnancy. However, they used an enzyme-linked immunosorbent assay (ELISA) originally developed by themselves (12) . The determination of reference values for sFlt-1 and PlGF using commercially available kits may have more clinical importance. In this study, we tried to construct reference curves representing the 90% confidence interval (90% CI) for sFlt-1, free PlGF, and the ratio of sFlt-1/PlGF throughout pregnancy using a commercially available ELISA kit (R&D Systems, Minneapolis, USA).
Methods

Participants and Specimens
With the informed consent of all the participants of this study and the approval of the Ethics Committee of our institute, peripheral blood samples were collected throughout the pregnancy period. Study subjects were 157 healthy Japanese women with singleton pregnancies attending antenatal clinics within 23 weeks of gestation. A total of 9 women were excluded from the analysis because they delivered at another hospital and details of the clinical outcome were unavailable.
Of the 148 women included in the study, 1 woman (0.7%) contributed one serum specimen (a case of preeclampsia), 49 (33.1%) contributed two specimens, 58 (39.2%) contributed three, and 40 (27.0%) contributed four.
For 33 of the 40 women from whom four specimens were collected, serum samples were collected at 8 to 12 weeks, 16 to 20 weeks, 26 to 30 weeks, and 35 to 39 weeks of gestation. In those women, we analyzed the data in a longitudinal man- ner. Preeclampsia was defined as a systolic blood pressure (SBP) ≥ 140 mmHg or a diastolic blood pressure (DBP) ≥ 90 mmHg, respectively, on 2 occasions recorded 24-h apart in association with the onset of proteinuria in a patient who had been normotensive during the first 20 weeks of pregnancy.
Procedure
Blood samples were collected and then centrifuged at room temperature at 2,500 rpm for 15 min. Serum aliquots were stored at -70°C until assayed. ELISAs for human sFlt-1 (also called soluble VEGF receptor 1) and free PlGF were performed in duplicate according to the manufacturer's instructions (R&D Systems). Briefly, the samples for ELISA measurements were diluted in 0.1% bovine serum albumin (BSA)/Tris-buffered saline and incubated in a 96-well plate precoated with a capture mouse monoclonal antibody directed against sFlt-1 or free PlGF for 2 h. The wells were then washed four times in 0.05% Tween 20/phosphate-buffered saline (PBS) and incubated with a secondary antibody against sFlt-1 and free PlGF conjugated to horseradish peroxidase for an additional 2 h. The plates were washed again four times, a substrate solution containing H2O2 and tetramethylbenzidine was added, and optical density was determined at 450 nm. A standard curve was generated for each sample plate, and sample concentrations of sFlt-1 and free PlGF were calculated with SoftMax 4-parameter logistic curve fit software (Molecular Devices Corp., Sunnyvale, USA). The minimal detectable doses in the assays for sFlt-1 and free PlGF were 5 and 7 pg/ml, respectively. The inter-assay and intraassay coefficients of variation were 7.6% and 3.3% for sFlt-1, and 10.9% and 5.6% for free PlGF, respectively.
Statistical Analysis
The results are presented as the mean±SD. For sFlt-1 and free PlGF, statistical testing was conducted after logarithmic transformation. Fisher's exact tests were used for the comparison of categorical variables, and unpaired t-tests or paired ttests were used for the comparison of two continuous variables if appropriate. All p values are two-tailed. All analyses were performed with the SPSS software package (version 13.0J for Windows; SPSS Inc., Chicago, USA). A level of p< 0.05 was considered statistically significant.
Results
Among the 148 women, preeclampsia occurred in 6⎯i.e., 4 women who delivered at < 37 weeks of gestation, and 2 who delivered at ≥ 37 weeks of gestation (Table 1 ). In 33 women for whom serial serum data were examined throughout the pregnancy, there was no preeclampsia ( Table 2 We used all 433 specimens from the 148 subjects, and calculated the average and 90% CI of the serum concentrations of sFlt-1 and free PlGF, and the ratio of sFlt-1/PlGF from 7 to 39 weeks. The averages at each week could be represented by a quadric curve (Fig. 2, Table 3 ). As the Levine tests for both Week of gestation sF lt-1/PlGF log10 sFlt-1 and log10 PlGF among weeks with the cases of n> 15 (at 8 to 11, 16 to 19, 27 to 29, and 37 weeks of gestation) were not significant (p= 0.391 and p= 0.479, respectively), we assumed that the SDs for both log10 sFlt-1 and log10 PlGF at each week were almost the same. However, the Levine tests for log10 sFlt-1/PlGF among weeks were slightly significant (p= 0.047), but the ranges of SD for log10 sFlt-1/ PlGF at each week showed no regular tendency of increase or decrease. Therefore, we presumed that the SD for log10 sFlt-1/ PlGF at each week was also almost the same. We estimated the SDs of the fitted curves by averaging the SDs at each week. The SDs for log10 sFlt-1, log10 PlGF, and the ratio of log10 sFlt-1/PlGF were 0.228, 0.242, and 0.291, respectively. Thus, the 5th and 95th percentile of log10 sFlt-1, log10 PlGF, and log10 sFlt-1/PlGF at each week were calculated by the equation, mean -1.645 × SD and mean + 1.645 × SD, respectively (Fig. 2, Table 3 
Discussion
In this study, we established the normal range of the serum concentration of both sFlt-1 and free PlGF throughout pregnancy. The concentration of sFlt-1 decreased from 8−12 weeks to 16−20 weeks, gradually increased at 26−30 weeks, and rapidly increased at 35−39 weeks of gestation. The concentration of free PlGF increased from 8−12 weeks to 26−30 weeks, and then decreased at 35−39 weeks of gestation. Thus, the cutoff value for abnormality should be changed according to the gestational period. In short, from 16 to 19 weeks of gestation, a level of free PlGF of < 58 pg/ml is abnormal, while after 20 weeks, a level < 100 pg/ml is abnormal. For sFlt-1, from 10 to 28 weeks of gestation, a level > 1,000 pg/ml is abnormal. However, at 35−39 weeks of gestation, 2,000 pg/ ml of sFlt-1 is within the normal range. Our reference value for free PlGF was slightly different from the value previously reported by Torry et al. (12) . The pattern of change during pregnancy was almost the same, but the levels at 28 to 30 weeks, and at term in Torry's report were slightly less than those in our report. These differences may have been due to the difference in anti-PlGF antibodies between the two ELISA kits. The ELISA kit used in this study was coated with a mouse monoclonal antibody against human PlGF, whereas the ELISA kit in the study by Torry et al. (12) was coated with rabbit anti-human PlGF. Torry et al. (12) used an ELISA originally developed by themselves. Because the ELISA kits that we used for this study were commercially available (R&D Systems), our reference value for free PlGF may be more useful for clinical studies.
We also established the reference values for the ratio of sFlt-1/PlGF. Because Maynard et al. (6) reported that angiogenesis was restricted by both the lower level of serum free PlGF in preeclamptic women and addition of exogenous sFlt-1 to the serum of non-pregnant women, the ratio of sFlt-1/ PlGF may represent the anti-angiogenic status in pregnant women. In our preliminary longitudinal study, the levels of log10 PlGF were all lower than the 5th percentile at 16−20 weeks in 4 women with both the subsequent onset of preeclampsia and preterm delivery (24 pg/ml at 17 weeks, 41 pg/ml at 17 weeks, 46 pg/ml at 18 weeks, and 54 pg/ml at 17 weeks; unpublished data). Our finding of a decrease in the concentration of free PlGF in the second trimester is consistent with previous reports which examined free PlGF levels at 13 to 28 weeks (7), 15 to 25 weeks (13), 16 to 20 weeks (14) , and 18 to 24 weeks (15), except for one study (16) . The levels of log10 PlGF at 8 to 12 weeks in 3 women with subsequent onset of preeclampsia and preterm delivery were all lower than the 5th percentile (7 pg/ml at 8 weeks, 17 pg/ml at 12 weeks, and 14 pg/ml at 12 weeks; unpublished data). This finding of a decrease in the concentration of PlGF in the first trimester is also in agreement with two previous reports which examined free PlGF levels at 5 to 15 weeks (14) , and 7 to 13 weeks (17) . Thus, data obtained by our group and other researchers (7, (13) (14) (15) 17) indicate that the level of free PlGF in both the first and the second trimester is decreased before the onset of preeclampsia.
Fig. 2. Quadric curves representing the mean and 5th and 95th percentile for the serum level of soluble fms-like tyrosine kinase 1 (sFlt-1) (A), placental growth factor (PlGF) (B), and the ratio of sFlt-1/PlGF (C) from
In our preliminary longitudinal study, the level of log10 sFlt-1 at 16 to 20 weeks in 4 women with both the subsequent onset of preeclampsia and preterm delivery (535 pg/ml at 17 weeks, 256 pg/ml at 17 weeks, 282 pg/ml at 18 weeks, and 613 pg/ml at 17 weeks; unpublished data) did not differ from that in normal pregnant women. This agrees well with the observation made by Levine et al. (7) that there were no differences in the serum sFlt-1 level at 17 to 20 weeks of gestation between normal and subsequent preeclampsia groups. However, Stepan et al. reported that the level of sFlt-1 was increased at 20 weeks of gestation in some women with findings of abnormal uterine perfusion on Doppler ultrasonography (18) . Therefore, a small fraction of preeclamptic patients may show an early increase in the concentration of sFlt-1 at around 20 weeks of gestation.
Levine et al. (7) reported that serum sFlt-1 levels in the highest quartile at 21 to 32 weeks and 33 to 41 weeks of gestation predicted the occurrence of preterm preeclampsia and term preeclampsia, respectively. In 2 cases of preeclampsia in our preliminary study, the levels of log10 sFlt-1 at around 28 weeks increased over the 95th percentile before the onset of preeclampsia (unpublished data). Thus, a higher sFlt-1 level after 21 weeks of gestation, but not before 21 weeks, is probably associated with an increased risk of preeclampsia.
In conclusion, we constructed quadric curves representing the 90% CI of sFlt-1, free PlGF, and the ratio of sFlt-1/PlGF throughout pregnancy. We also established cutoff values of sFlt-1, free PlGF, and the ratio of sFlt-1/PlGF for identifying pregnant women at risk for the subsequent onset of preeclampsia. In our preliminary cohort study, the levels of free PlGF in the second trimester in 4 women with the subsequent onset of preeclampsia with preterm delivery were all below the 5th percentile. However, we studied only a small number of women. The present findings need to be confirmed in larger studies.
